| |
Hemorphin-7  |
|
|
| Cat. No. |
Size |
Price |
Figures |
|---|
RP17312-1 mg
| 1 mg | $ 66.00 | MSDS: 20080915224050 (PDF)
STRUCTURE:
Zoom
References:
- Hunyady L, Catt KJ. Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. Mol Endocrinol. May 2006;20(5):953-70.
- Szikra J, Benyhe S et al. Radioligand binding properties of VV-hemorphin 7, an atypical opioid peptide. Biochem Biophys Res Commun. Mar 2001;281(3):670-7.
- Lee J, Mustafa T et al. Structure-activity study of LVV-hemorphin-7: angiotensin AT4 receptor ligand and inhibitor of insulin-regulated aminopeptidase. J Pharmacol Exp Ther. Apr 2003;305(1):205-11.
|
|---|
| Full Name | |
| Alias |
Hemorphin7 |
Sequence
(one-letter code) |
YPWTQRF | Sequence
(three-letter code) | {TYR}{PRO}{TRP}{THR}{GLN}{ARG}{PHE} |
|---|
| Description | Hemorphins are endogenous peptides belonging to the family of atypical opioid peptides that are released from sequentially hydrolyzed hemoglobin, the first sequence implicating a hemoglobin cathepsin D proteolysis. hemorphin-7 binds with high affinity to the angiotensin IV (Ang IV) receptor (AT(4) receptor), eliciting a number of physiological effects, including cellular proliferation and memory enhancement. |
|---|
| Formula | C49H64N12O11 |
|---|
| M.W. | 997.11 |
|---|
| Purity | > 95% |
|---|
| Storage | Store at -20°C. Keep tightly closed. Store in a cool dry place. |
|
